test

Developmental Therapeutics

Joseph Paul Eder MD

Professor of Medicine (Medical Oncology)

Clinical Interests

Some particular areas of past and present involvement in the development of novel therapeutics include high dose chemotherapy, the modulation/ reversal of drug resistance, growth factors, vaccines, signal transduction pathway inhibitors, cell cycle inhibitors, and the therapeutic use of antiangiogenisis agents. In this area, I have interest in developing pharmacodynamic markers of antiangiogenic effects in the clinic including MRI and PET imaging, circulating endothelial cells, monitoring interstitial fluid pressures and the evaluation of tumor biopsies after therapy. The clinical role of pathways to resistance is an area of interest and I have led clinical trials of HGF/MET inhibitors combined with VEGF-targeted therapies.


Board Certifications

1984
Hematology (Internal Medicine), Board Certified
1981
Internal Medicine, Board Certified
1983
Medical Oncology, Board Certified

Patient Care Locations

joseph_ederfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Colorectal Cancer and ColonA Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer (CALGB 80702)
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Bladder, Breast - Female, Colon, Lung, Melanoma, skin, Other Endocrine System, Other Respiratory and Intrathoracic Organs, Other Urinary, Ovary, Rectum, and StomachA Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
Breast - Female, Colon, Esophagus, Kidney, Liver, Lung, Melanoma, skin, and PancreasA Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors
Bladder, Brain and Nervous System, Breast - Female, Colon, Esophagus, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Endocrine System, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, and ThyroidMy Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients Who Have Advanced Cancer with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents PRO-02

More Clinical Trials...

Edit Profile